Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 11/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18725651 | 1.00 | IDH1 (0.47) | IDH1NR3C2MTORPIK3CAKMT2A | |
| SCHEMBL18810150 | 1.00 | IDH1 (0.47) | IDH1NR3C2MTORPIK3CAKMT2A | |
| SCHEMBL5604547 | 0.86 | IDH1 (0.55) | IDH1MTORPIK3CAGRM2 | |
| SCHEMBL5604553 | 0.86 | IDH1 (0.55) | IDH1MTORPIK3CAGRM2 | |
| SCHEMBL14556276 | 0.81 | L3MBTL1 (0.50) | IDH1NR3C2MTORPIK3CAKMT2A | |
| SCHEMBL14556299 | 0.81 | L3MBTL1 (0.50) | IDH1NR3C2MTORPIK3CAKMT2A | |
| SCHEMBL14556277 | 0.81 | L3MBTL1 (0.50) | IDH1NR3C2MTORPIK3CAKMT2A | |
| SCHEMBL4497765 | 0.79 | AR (0.51) | IDH1NR3C2KMT2A | |
| SCHEMBL5428237 | 0.77 | TNKS (0.46) | IDH1 | |
| SCHEMBL5428231 | 0.77 | TNKS (0.46) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3812040-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2023-01-11 | — | — | EP | disclosed |
| EP-3812040-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-3154689-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2021-01-27 | — | — | EP | disclosed |
| US-9777030-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-03 | — | — | US | disclosed |
| US-20170120231-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-3154689-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170120231-A1 | COMPLEXES | AP3M1, CYCS, AP1M1 | IDH1 132/4885NR3C2 903/4885MTOR 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.